Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01TVQ
|
|||
| Former ID |
DAP000383
|
|||
| Drug Name |
Ibritumomab
|
|||
| Synonyms |
Zevalin (TN)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Approved | [1] | |
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 2 | [2], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bayer Pharmaceuticals Corporation
|
|||
| SuperDrug ATC ID |
V10XX02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [4] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6777). | |||
| REF 3 | Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003 Apr;18(2):165-78. | |||
| REF 4 | Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.